Green Thumb Indus Sub Vtg (GTBIF)

Analysts think this top cannabis stock could more than double -- in only 12 months.

These stocks come with risk, but they also have some exciting long-term growth opportunities.

These companies are major players in the U.S. marijuana market, and they all generated more than $1 billion in revenue last year.

The Trump administration recently rescheduled medical marijuana from a Schedule I to Schedule III substance.

A recent licensing change could pave the way for higher profits.

Err on the side of caution with this falling knife.

The company has a tough road ahead.

Green Thumb's dismal stock performance doesn't reflect the strength of its underlying business.

The cannabis company's shares have plummeted by more than 40% over the past year.

Rescheduling cannabis to a Schedule 3 drug, if it happens, represents a long-term industry tailwind.

Green Thumb expects to generate significantly more free cash flow due to marijuana's rescheduling.

As of January 9, 2026, the cannabis sector finds itself at a historic crossroads, caught between the euphoria of federal progress and the harsh reality of market mechanics. Following a landmark Executive Order in late 2025 aimed at accelerating the rescheduling of marijuana, the industry has entered the new year

Not all of these predictions may come true. But at least a few of them will likely do so.

President Donald Trump just signed an executive order that reclassified marijuana from a Schedule I narcotic to Schedule III.

These cannabis companies could soon see more green thanks to the president's milestone decision.

Trump's historic executive order to reclassify cannabis isn't the victory it appears to be.

The cannabis sector is experiencing a historic "Santa Claus rally" this December, with stock prices surging across the board following a transformative shift in federal policy. Today, December 19, 2025, markets are still reeling from yesterday’s decisive executive action aimed at ending the federal gridlock that has plagued the

In a move that has sent shockwaves through the global financial markets, the cannabis sector is currently navigating a period of unprecedented volatility following a landmark regulatory shift. On December 18, 2025, President Donald Trump signed a historic Executive Order directing the Attorney General to expedite the reclassification of marijuana

For hardly the first time in recent days, investors have become excited about the prospect of a significant change in U.S. drug laws.

The cannabis industry is enjoying renewed momentum under Trump, whose administration has adopted a notably more accommodative approach toward the drug and its related products.

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare.

The U.S. government funding bill to end the shutdown included language tightening rules on hemp-derived THC products.

Congress appears set to end the record-long government shutdown, but a controversial provision tucked into the spending bill is sparking alarm across the hemp and cannabis industry.